What is CDXS stock price today?

CDXS (Codexis Inc) stock is trading at $2.59 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is CDXS stock going up or down today?

CDXS stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy CDXS stock now?

The decision to buy CDXS depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is CDXS a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for CDXS based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is CDXS stock overvalued or undervalued?

Use our DCF valuation calculator to determine if CDXS is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is CDXS's P/E ratio?

P/E ratio data for CDXS will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is CDXS's market cap?

CDXS (Codexis Inc) has a market capitalization of $0.23 billion, making it a small-cap stock.

What is CDXS's price to book ratio?

CDXS trades at a price-to-book (P/B) ratio of 4.41, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does CDXS pay dividends?

CDXS does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is CDXS's dividend yield?

CDXS does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is CDXS stock a good long-term investment?

CDXS's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is CDXS's revenue growth rate?

CDXS has shown revenue growth of 0.8% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

CDXS is currently operating at a loss. Some companies prioritize growth over profitability in early stages. Review our financial analysis for detailed insights.

What are the risks of investing in CDXS?

Key risks for CDXS include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does CDXS compare to its competitors?

Compare CDXS to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize CDXS's performance and positioning.

What is CDXS's stock price target for 2026?

Our AI model provides price targets for CDXS based on fundamental analysis: Bull case $3.37 (+30%), Base case $2.98 (+15%), Bear case $2.33 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about CDXS?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for CDXS. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is CDXS's next earnings report?

CDXS reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

CDXS - Codexis Inc

NYSE * Health Care * Biotechnology

$2.59

+$0.05 (+1.97%)

About Codexis Inc

Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.

CDXS Key Statistics

Market Cap

$230.81M

P/B Ratio

4.41

EPS

$-0.50

Revenue Growth

+0.8%

Profit Margin

-0.6%

Employees

146

How CDXS Compares to Peers

CDXS has the fastest revenue growth among competitors

CDXS is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
CDXS(This stock)	$230.81M	N/A	1%	-0.6%	-
AMGNAmgen Inc	$188.34B	24.6	0%	0.2%	vs AMGN
GILDGilead Sciences	$171.97B	20.4	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$110.81B	28.4	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$78.87B	18.0	0%	0.3%	vs REGN
BIIBBiogen Inc	$26.03B	20.0	-0%	0.1%	vs BIIB

Codexis Inc Company Information

Headquarters: California; U.S.A
Website: www.codexis.com
Sector: Health Care
Industry: Biotechnology

CDXS - Codexis Inc

About Codexis Inc

CDXS Key Statistics

How CDXS Compares to Peers

Codexis Inc Company Information

CDXS Lician Score

CDXS Financial Snowflake

Upcoming Events for CDXS